{"url_path":"/sec/cing/8-k/2026-07-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1862150/0001493152-26-031668-index.html","accession_number":"0001493152-26-031668","cik":"0001862150","ticker":"CING","issuer_name":"Cingulate Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1862150/0001493152-26-031668-index.html","primary_entity_key":"0001862150","primary_entity_name":"Cingulate Inc."},"word_count":97,"has_tables":true,"body_markdown":"**Item 9.01.**\n**Financial Statements and Exhibits**\n\n \n\n(d)\nExhibits\n\n \n\nExhibit No.\n \nDescription\n\n \n \n \n\n10.1\n \n[Amendment to Employment Agreement, effective June 30, 2026, between Cingulate Therapeutics, LLC and Matthew N. Brams](ex10-1.htm)\n\n \n \n \n\n99.1\n \n[Press Release, dated July 2, 2026](ex99-1.htm)\n\n \n \n \n\n104\n \nCover Page Interactive\nData File (embedded within the Inline XBRL document)\n\n** **\n\n \n\n \n\n** **\n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**CINGULATE INC.**\n\n \n \n \n\nDated: July 2, 2026\nBy:\n*/s/ Shane J. Schaffer*\n\n \nName:\nShane J. Schaffer\n\n \nTitle:\nChief Executive Officer"}